Atrinsic Inc. (NASDAQ:PTIX) Short Interest Update

Atrinsic Inc. (NASDAQ:PTIX) was the target of a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 50,768 shares, a drop of 17.7% from the December 15th total of 61,712 shares. Based on an average daily volume of 53,322 shares, the days-to-cover ratio is currently 1.0 days. Approximately 2.9% of the shares of the company are sold short. Approximately 2.9% of the shares of the company are sold short. Based on an average daily volume of 53,322 shares, the days-to-cover ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Atrinsic in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Atrinsic Stock Down 15.1%

Shares of PTIX traded down $0.09 during midday trading on Tuesday, reaching $0.50. 5,336 shares of the stock were exchanged, compared to its average volume of 236,692. The stock’s 50 day simple moving average is $1.45 and its 200 day simple moving average is $2.61. The company has a market cap of $968,854.50, a P/E ratio of -0.06 and a beta of 0.51. Atrinsic has a twelve month low of $0.26 and a twelve month high of $14.28.

Atrinsic (NASDAQ:PTIX) last released its quarterly earnings results on Wednesday, November 26th. The company reported ($0.47) EPS for the quarter.

Atrinsic Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.